StonvexLoading…
StonvexStonvexStonvexCore line items from LUNG's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $20.59M | $90.50M | $67.90M | $46.40M |
Operating Income | $-12.96M | $-53.66M | $-43.76M | $-29.37M |
Net Income | $-13.65M | $-54.00M | $-43.58M | $-15.17M |
EPS (Diluted) | $-0.33 | $-1.33 | $-1.08 | $-0.74 |
Total Assets | $119.97M | $129.29M | $138.28M | $147.19M |
Total Liabilities | $74.20M | $75.17M | $78.25M | $78.10M |
Cash & Equivalents | $61.57M | $69.75M | $76.55M | $75.47M |
Free Cash Flow OCF − CapEx | $-10.11M | $-32.83M | $-25.73M | $-17.48M |
Shares Outstanding | 42.24M | 41.67M | 41.25M | 40.74M |